Adicet bio, inc. announces pricing of public offering

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (“adicet”) (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 8,445,333 shares of common stock. the shares of common stock are being sold at.
ACET Ratings Summary
ACET Quant Ranking